Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

2.210 -0.070 (-3.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Telomir Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
Get insights into the top gainers and losers of Monday's pre-market session.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Top stock movements in today's session.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Most active stocks in Friday's session
Discover the most active stocks in Friday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Falls Over 200 Points; 3M Earnings Top Views
Via Benzinga
Topics Stocks
On Friday, there are stocks with unusual volume. Let's take a look.
On Friday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
Friday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Gapping stocks in Friday's session
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
US Stocks Mixed; American Express Posts Upbeat Q2 Results
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Higher After Scaling Record Close: American Express, 3M, Charles Schwab Earnings In Focus
U.S. stock futures were positive on Friday after ending higher on Thursday. Futures of major benchmark indices were higher. 
Via Benzinga
Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests
Following the announcement of promising data regarding Telomir-1, Telomir Pharmaceuticals Inc stock surged 138.84% during after-hours trading on Thursday, 
Via Benzinga
Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains
The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Thursday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria
Telomir-1 improved cell survival, reduced oxidative stress, and restored mitochondrial balance in preclinical progeria study. 
Via Benzinga
These stocks are moving in today's pre-market session
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder
Telomir-1 boosted telomere length, restored weight and muscle, and cut oxidative stress in a preclinical Werner Syndrome animal model. 
Via Benzinga
These stocks that are showing activity before the opening bell on Monday.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND
Telomir Pharma (NASDAQ: TELO) secured $3M in equity financing from Bayshore Trust, its largest shareholder, at $3 per share (18% premium). It also has a $5M credit line. It has 2 innovative drug... 
Via Benzinga
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction. 
Via Benzinga
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration
Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions. 
Via Benzinga
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation. 
Via Benzinga
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation 
Via News Direct
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.